OncoPLEX
Single ingredient · 120 servings · $-0.01 · 4.2 stars from 23 reviews
Not backed for Cardiovascular health
May not help: inflammation signal (TNF-α)
- Evidence Not backed
- Dose 1 of 1 at a studied dose
- Safety Read the label's warnings
- Fillers None of concern
What's in it
The dose here lands inside the range studies actually used.
Supplement Facts
Serving Size: 1 Capsule(s)
120 per container
- TrueBroc as Glucoraphanin May help a little · Lower cancer risk › 30 mg †
† Daily Value not established
Other ingredients: Microcrystalline Cellulose, Hypromellose, Water, Stearic Acid, Magnesium Stearate, Silica.
Directions: Take one capsule daily, or as directed by your healthcare professional.
Doses against the trials
-

TrueBroc
At the studied dose
30 mg a day studies used 30–102 mg · 4 studies
What it's sold for
-
Cardiovascular health
Not backed
-
Antioxidant support
Unproven
-
Detoxification
Unproven
-
Immune support
Unproven
-
Nervous system health
Unproven
-
Detox support
Unproven
-
Liver health
Unproven
Worth knowing
The label's warnings
Consult your healthcare professional prior to use.
Individuals taking medication should discuss potential interactions with their healthcare professional.
Storage: Keep closed in a cool, dry place out of reach of children.
Reported side effects
Fracture, Bloating
The other ingredients
A few additives worth noting in the inactive ingredients.
- Microcrystalline Cellulose: bulking agent
- Hypromellose: capsule shell material
- Water
- Stearic Acid: flow agent; fine in trace
- Magnesium Stearate: flow agent; fine in trace
- Silica: flow agent; inert but filler
Free from
Vegan, Vegetarian, Gluten Free, Dairy Free. Formulated to Exclude: Wheat, gluten, corn, yeast, soy, animal and dairy products, fish, shellfish, peanuts, tree nuts, egg, sesame, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.
XYMOGEN
80 out of 100
Brand audit score
XYMOGEN shows a solid quality posture with NSF Certified for Sport listings and public company disclosures, but the available evidence remains limited.